<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02834390</url>
  </required_header>
  <id_info>
    <org_study_id>AC220-A-J102</org_study_id>
    <nct_id>NCT02834390</nct_id>
  </id_info>
  <brief_title>Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>Phase 1b, Open-label, Dose Escalation Study of Quizartinib in Combination With Induction and Consolidation Chemotherapy in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b, dose escalation, study of quizartinib to evaluate the safety profile, the
      pharmacokinetics, and the recommended dose of quizartinib for subsequent clinical studies of
      the combination of quizartinib and induction and consolidation chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">October 19, 2017</completion_date>
  <primary_completion_date type="Actual">October 19, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects experiencing adverse events</measure>
    <time_frame>day 0 to end follow-up, approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax profile of quizartinib and its active metabolite</measure>
    <time_frame>Induction cycle 1 day 8 to consolidation cycle 1 day 28</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax profile of quizartinib and its active metabolite</measure>
    <time_frame>Induction cycle 1 day 8 to consolidation cycle 1 day 28</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau profile of quizartinib and its active metabolite</measure>
    <time_frame>Induction cycle 1 day 8 to consolidation cycle 1 day 28</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss profile of quizartinib and its active metabolite</measure>
    <time_frame>Induction cycle 1 day 8 to consolidation cycle 1 day 28</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ctrough profile of quizartinib and its active metabolite</measure>
    <time_frame>Induction cycle 1 day 8 to consolidation cycle 1 day 28</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax,ss profile of quizartinib and its active metabolite</measure>
    <time_frame>Induction cycle 1 day 8 to consolidation cycle 1 day 28</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau,ss profile of quizartinib and its active metabolite</measure>
    <time_frame>Induction cycle 1 day 8 to consolidation cycle 1 day 28</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quizartinib and Cytarabine to be used in both the Induction period and the Consolidation period.
And either Idarubicin or Daunorubicin to be used in the Induction period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quizartinib</intervention_name>
    <description>[Induction period] Once-daily repeated oral administration day 8 to day 21. [Consolidation period] Once-daily repeated oral administration day 6 to day 19.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>[Induction period] Once-daily intravenous injection of 100 mg/m2 cytarabine on day 1 to 7.
[Consolidation period] Twice-daily intravenous injection of 3.0 g/m2 cytarabine at 12-hour intervals on day 1, 3, and 5.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>Either Idarubicin or Daunorubicin will be used [Induction period] Once-daily intravenous injection of 12 mg/m2 idarubicin on day 1 to 3.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Either Idarubicin or Daunorubicin will be used [Induction period] Once-daily intravenous injection of 60mg/m2 daunorubicin on day 1 to 3.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No prior treatment for AML (including quizartinib)

          -  ECOG (Eastern Cooperative Oncology Group) Performance Status of 0 to 2

        Exclusion Criteria:

          -  Diagnosis of acute promyelocytic leukemia

          -  Active acute or chronic systemic fungal, bacterial, or viral infection not well
             controlled by antifungal, antibacterial or antiviral therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2016</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>phase 1</keyword>
  <keyword>hematology</keyword>
  <keyword>malignancy</keyword>
  <keyword>newly diagnosed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

